Semaglutide is not just for diabetes: what the evidence says

What did @draleslieheredia actually say?

Honestly, this is a tough one to fact-check, because the transcript is nearly incoherent. The video's Spanish caption asks whether semaglutide, better known as Ozempic, is "only a medication for patients with diabetes." That's the real claim here. But the English transcript, which appears to be a machine translation or auto-caption failure, contains no meaningful medical content whatsoever. Lines like "I'm going to know how to feel about it" and "we have to stay in the hospital for a while" don't map to any coherent medical argument. So we're working with the caption's implied question: is Ozempic diabetes-only?

That question is legitimate and worth answering. With 102,700 views, a lot of people are going to walk away from this video with some impression about semaglutide's approved uses, even if the actual spoken content couldn't be parsed reliably.

Does the science back this up?

No, semaglutide is not only for diabetes patients. That's the short answer, and it's well supported. The FDA approved semaglutide under the brand name Wegovy specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition in June 2021. This approval was based on the STEP trials, a landmark series of randomized controlled trials.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) enrolled adults without diabetes and found that once-weekly subcutaneous semaglutide 2.4 mg produced a mean weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo. That's a clinically significant difference. Ozempic, the 0.5 mg and 1 mg formulation, remains approved for type 2 diabetes. Wegovy, the 2.4 mg formulation, is approved for weight management. Same molecule, different doses, different indications. Conflating the two brand names is a common error in social media health content.

What did they get wrong (or right)?

The caption gets the underlying question right. A lot of people genuinely don't know that semaglutide has an FDA-approved weight loss indication separate from its diabetes use. Raising that question for a Spanish-speaking audience is useful public health communication, at least in theory.

What we can't evaluate is whether the creator's actual spoken explanation was accurate, because the transcript is unusable. That's a real problem. Health content that reaches over 100,000 viewers should be reviewable. If the auto-caption fails this badly, it raises a question about accessibility and accountability. Creators in regulated health spaces should ensure their content is accurately transcribed, especially when discussing prescription medications.

There's also no visible disclaimer in the caption about semaglutide requiring a prescription, medical supervision, or individual clinical evaluation. The hashtag "acompañamientopsicologico" (psychological support) is a reasonable nod to comprehensive care, but it doesn't substitute for a proper disclosure.

What should you actually know?

Semaglutide exists under multiple brand names with different approved uses. Ozempic (0.5 mg, 1 mg, 2 mg) is FDA-approved for type 2 diabetes and, as of 2024, for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, based on the SELECT trial (Lincoff et al., 2023, New England Journal of Medicine). Wegovy (2.4 mg) is approved for chronic weight management.

These are not interchangeable prescriptions. A person without diabetes being prescribed Ozempic for weight loss is using it off-label. That's legal and common in clinical practice, but it's meaningfully different from being prescribed Wegovy, which carries its own label, dosing schedule, and insurance coverage pathway. Compounded semaglutide, which became widely available during the shortage period, is not equivalent to either brand-name product and carries its own regulatory history.

If you're considering semaglutide for weight management, that conversation needs to happen with a licensed clinician who can review your full medical history, not based on a 60-second TikTok video.

The bottom line

The question posed in this video's caption is a good one. The answer is clearly no, semaglutide is not only for diabetes. But we can't tell from this video whether the creator actually explained that accurately, because the transcript is a garbled mess. What we can say is that the underlying science supports dual indications for semaglutide, the distinction between brand names and doses matters clinically, and anyone making health decisions based on social media content about prescription GLP-1 medications should loop in a medical provider before acting on anything they see.